Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Minimal residual disease-guided adjuvant tislelizumab after adjuvant chemotherapy in resected stage IIA-IIIB NSCLC: A single-arm phase II study (Seagull)

Trial in progress

ESMO Asia Congress 2022